Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tirzepatide (Primary)
Indications Obesity
Focus Pharmacodynamics
Acronyms TREASURE-CKD
Sponsors Eli Lilly and Company

Most Recent Events

03 Dec 2024 Planned End Date changed from 26 Feb 2026 to 1 Feb 2026.
03 Dec 2024 Planned primary completion date changed from 29 Jan 2026 to 1 Jan 2026.
11 Sep 2023 Planned End Date changed from 7 Nov 2025 to 26 Feb 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight